Effect comparison between peginterferon α-2a and telbivudine in treatment of patients with HBeAg positive chronic hepatitis B and predictive factor for HBeAg seroconversion
-
摘要: 目的：比较聚乙二醇干扰素α-2a 与替比夫定（LDT）治疗 HBeAg 阳性慢性乙型肝炎（CHB）的疗效。方法选取HBeAg 阳性慢性乙型肝炎患者71例，分为聚乙二醇干扰素α-2a 组33例和 LDT 组38例。比较2组治疗48周的疗效，并分析HBeAg 血清学转换的相关因素。结果治疗48周时，聚乙二醇干扰素α-2a 组和 LDT 组血清 HBV DNA 转阴率分别为54．5％和78．9％（P ＜0．05），ALT复常率分别为60．6％和81．5％（P ＜0．05），HBeAg血清转换率分别为36．4％和28．9％（P ＞0．05）。2组患者在治疗48周时 HBeAg 血清转换与基线ALT、HBV DNA 水平、HBeAg 水平无显著相关性（P ＞0．05）。多因素Logistic 回归分析显示，聚乙二醇干扰素α-2a 组治疗48周时 HBeAg 血清转换率与12、36、24周时 HBeAg 下降大于2log 相关；TLD 组治疗48周时 HBeAg 血清转换率与36、24、12周时 HBeAg 下降大于2log 相关。结论 TLD 组较聚乙二醇干扰素α-2a组有更高的 HBV DNA 转阴率及 ALT 复常率。36周 HBeAg 较基线下降大于2log 可作为2组患者治疗48周时 HBeAg 血清转换的最佳预测因素。12周时 HBeAg 较基线下降大于2log 作为聚乙二醇干扰素α-2a 组治疗48周时 HBeAg 血清转换最佳预测因素，36周 HBeAg 较基线下降大于2log 作为 TLD 组治疗48周时 HBeAg 血清转换最佳预测因素。Abstract: Objective To compare the therapeutic effect between peginterferonα-2a and tel-bivudine (TLD)in treatment of patients with HBeAg positive chronic hepatitis B (CHB).Methods 71 patients with HBeAg positive CHB were divided into peginterferonα-2a group (n =33)and TLD group (n =38).Efficacy was compared and the HBeAg seroconversion factors were analyzed. Results 48 weeks after treatment,the negative conversion rates of serum HBV DNA in peginter-feronα-2a group and TLD group were 54.5% and 78.9% (P <0.05)respectively,the ALT nor-malization rates were 60.6% and 81.5% (P <0.05)respectively,the HBeAg seroconversion rates were 36.4% and 28.9% (P >0.05)respectively.There was no significant correlation between HBeAg seroconversion and ALT,HBV DNA HBeAg levels.The logistic regression analysis showed that the HBeAg seroconversion ratio in the peginterferonα-2a group at the 48th week was closely re-lated to 3 factors:the HBeAg decreased more than 2log at the 12th,24th and 36th week.The HBeAg seroconversion ratio in theTLDgroup at the4 8 thweekwas closely associatedwith 3 factors :the HBeAg decreased more than 2 log at the 3 6 th ,2 4 th and 1 2 th week .Conclusion The negative conversion rate of HBV DNA and ALT normalization rate in patients with HBeAg posi-tive CHB after 48 weeks therapy in TLD group are higher than those in peginterferonα-2a group. The HBeAg decreased more than 2log from the baseline to the 36th week can be used as the best predictor for the HBeAg seroconversion rate after the 48th week therapy in both groups.The HBeAg decreased more than 2log from the baseline to the 12th week can be used as the best pre-dictor for the HBeAg seroconversion rate after the 48th week therapy in the peginterferonα-2a group,and the HBeAg decreased more than 2log from the baseline to the 36th week can be used as the best predictor for the HBeAg seroconversion rate after the 48th week therapy in the TLD group.
-
Keywords:
- hepatitis virus /
- hepatitis B /
- hepatitis E antigen /
- peginterferonα-2a /
- tel-bivudine
-
-
期刊类型引用(10)
1. 方敏华. 三球式呼吸训练器训练应用于无创正压通气治疗慢性阻塞性肺疾病患者的效果分析. 基层医学论坛. 2024(11): 35-37 . 
百度学术
2. 许明璐，杨萧含，刘倩楠，尹畅. 老年人慢性病共病关联规则分析. 实用临床医药杂志. 2024(13): 103-108 . 本站查看
3. 尹宁宁，王志娟，张海霞. 慢性阻塞性肺疾病患者并发心血管疾病危险因素及预测模型建立. 川北医学院学报. 2023(05): 608-612 . 百度学术
4. 陈婷，陈丹凤，翁克姬. 负荷拓展呼吸训练联合血糖控制对慢阻肺合并高血压患者肺功能及血压控制效果的影响. 心血管病防治知识. 2023(18): 83-85 . 百度学术
5. 黎玲，林丽芳. 自我管理对慢性阻塞性肺疾病合并高血压患者肺功能及生活质量的影响研究. 心血管病防治知识. 2023(22): 73-75 . 百度学术
6. 曾丹虹. 多学科协作干预对AECOPD合并高血压患者肺功能的影响. 心血管病防治知识. 2023(25): 42-44 . 百度学术
7. 陈春红. 自我管理对慢性阻塞性肺疾病合并高血压患者肺功能及生活质量的影响. 心血管病防治知识. 2022(06): 65-67 . 百度学术
8. 陈芳，孙莲. 老年高血压伴慢性阻塞性肺疾病患者临床研究进展. 实用医院临床杂志. 2022(03): 229-231 . 百度学术
9. 王龙龙，许淑娣，马洪鸽，马静文，王警建，杨淑涵，张明. 慢性阻塞性肺疾病合并抑郁患者的脑皮质边缘环路研究. 实用临床医药杂志. 2022(11): 38-41 . 本站查看
10. 石婷婷，刘双全，高晓华，张锋英. 慢性阻塞性肺疾病合并社区获得性肺炎患者的临床特征及其影响因素分析. 医学信息. 2022(19): 38-42 . 百度学术
其他类型引用(6)
计量
- 文章访问数: 282
- HTML全文浏览量: 46
- PDF下载量: 0
- 被引次数: 16
下载:
苏公网安备 32100302010246号
